Latest Conference Coverage

Paul George, MD, PhD, FAAN, a board member of the American Academy of Neurology (AAN), gave an inside look at what clinicians can expect from the upcoming AAN Annual Meeting, held April 18-22 in Chicago.

The senior vice president of clinical development for Lundbeck discusses the mechanism and early clinical promise of Lu AF28996, an oral dual D1/D2 agonist for advanced Parkinson disease. [WATCH TIME: 3 minutes]

Diana Castro, MD, founder and director of the Neurology and Neuromuscular Care Center, discussed early phase 1b data on salanersen, an investigational therapy for patients living with spinal muscular atrophy.

The director of neuromuscular medicine at Marcus Neuroscience Institute shared findings from an analysis presented at MDA 2026 that compared real-world infection rates associated with generalized myasthenia gravis therapies. [WATCH TIME: 8 minutes]

A neuroimmunology fellow at the Cleveland Clinic shared her experience attending the 2026 ACTRIMS Forum, specifically focusing on the late-breaking data presented in multiple sclerosis.

A neuroimmunology fellow at the Cleveland Clinic reflected on the 2026 ACTRIMS Forum, highlighting key takeaways in multiple sclerosis research presented in the program. [WATCH TIME: 6 minutes]

Nazem Atassi, MD, SVP and Global Development Head of Neurology & Gene Therapy at Novartis, discussed 64-week STEER data and the evolving role of one-time gene therapy in SMA care.

The founder and CEO at the Hereditary Neuropathy Foundation discussed how learning about patient experiences has influenced research in Charcot-Marie-Tooth disease. [WATCH TIME: 5 minutes]

The chief medical officer at Edgewise discussed long-term MESA data showing sustained functional stabilization with sevasemten in Becker muscular dystrophy and its potential as a disease-modifying therapy.

The 2026 MDA National Ambassador discussed the importance of connecting patients’ experiences with scientific understanding, as well as fostering a sense of community among those living with neuromuscular disease. [WATCH TIME: 2 minutes]

Phase 2 findings indicated that the investigational agent zervimesine exhibited a favorable safety profile and may slow disease progression in patients with mild to moderate dementia with Lewy bodies.

The assistant professor of medicine at the University of Toronto discussed population-level evidence suggesting MS may precede EBV infection in rare cases and its implications for disease pathogenesis and diagnosis.

A new retrospective analysis presented at AD/PD 2026 showed that cutaneous phosphorylated α-synuclein testing reduced diagnostic and management-related health care expenditures.

An analysis of baseline data from the phase 2b LUMA study suggested that keystroke dynamics captured through a smartphone-based typing task could provide a reliable method for assessing disease progression in Parkinson disease.

The research portfolio director at the Muscular Dystrophy Association highlighted the collaborative spirit, the expanding therapeutic pipeline, and the growing emphasis on patients’ voices in neuromuscular disease on display at MDA 2026. [WATCH TIME: 8 minutes]

Early ASPIRO trial data show autologous stem-cell dopamine precursors stay safe at 12 months, with improved PD motor scores and PET-confirmed grafting.

MRI-guided focused ultrasound steers IV gene therapy to mouse brains, lowering cortical tau—though hippocampal response stays absent.

Phase 1 data suggest plasma GFAP levels may correlate with cognitive outcomes in patients with Alzheimer disease treated with troculeucel, an investigational autologous NK-cell therapy.

Two phase 3 ADAGIO trials test Cobenfy for Alzheimer’s agitation, assessing muscarinic modulation safety and efficacy as a potential new dementia care option.

The child neurologist at Children’s Hospital of Philadelphia discussed the real-world safety data of givinostat use in patients with Duchenne muscular dystrophy at the 2026 MDA Conference. [WATCH TIME: 5 minutes]

UK platform trial enrolls 1,600 with Parkinson’s to rapidly test telmisartan, terazosin and new candidates via shared placebo and virtual visits.

The professor of neurology at Cleveland Clinic’s Mellen Center for MS provided thoughts on how radiologic biomarkers may help shape the next generation of multiple sclerosis clinical trials. [WATCH TIME: 3 minutes]

Early BB-301 gene therapy data show durable swallowing gains and benign safety in OPMD dysphagia, hinting at disease modification.

Phase 3 data show Ultragenyx’s DTX301 gene therapy lowers ammonia in OTC deficiency, easing symptoms and reducing reliance on restrictive diets.

A phase 1/2 study aims to assess the safety and tolerability of nivudirsen, also known as BMN 351, in single ascending and multiple ascending doses among patients living with Duchenne.

A neurologist at Georgetown University, MedStar Health, discussed phase 2/3 data presented at the 2026 MDA Conference that supports efgartigimod as a novel treatment for inflammatory myopathies. [WATCH TIME: 2 minutes]

A retrospective cohort study reported that myocardial fibrosis detected by cardiac MRI was associated with higher fatigue scores among women carriers of Duchenne or Becker muscular dystrophy.

At the 2026 MDA Conference, a neurologist at Nemours Children's Hospital discussed practical strategies for navigating insurance to ensure patients can access newly available neuromuscular therapies. [WATCH TIME: 3 minutes]